Previous 10 | Next 10 |
Prothena (PRTA) prices offering of 3.5M shares at $20.75/share.The net proceeds from the offering will be ~$67.8M.Underwriters' option to purchase up to an additional 0.525M shares.The offering is expected to close by March 26.Shares -1% premarket.Previously (March 23): Prothen...
DUBLIN, Ireland, March 24, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced that i...
Prothena (PRTA) has commenced an underwritten public offering of common shares.The number of shares in the offering and price has not yet been determined.Citigroup, Jefferies and Cantor are acting as joint book-runners.Underwriters have been granted a 30-day option to purchase up to an additi...
DUBLIN, Ireland, March 23, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced that i...
Superior profile of novel anti-tau antibody PRX005 supports advancement for the potential treatment of Alzheimer’s disease New analyses of prasinezumab continue to support potential disease modifying effect of prasinezumab in Parkinson’s disease; Roche expected to ...
Fate Therapeutics (FATE) initiated with a Buy at BofA Securities. PT set to $115, implies a 33% increase from last price.Wedbush analyst David Nierengarten downgraded FATE to Neutral from Outperform as it sees “higher downside risk”and less reward as clinical programs advance an...
Robust preclinical data support the benefit of PRX005, a novel anti-tau antibody, for the potential treatment Alzheimer’s disease New pre-specified exploratory subgroup analyses and new digital biomarker data from Part 1 of the Phase 2 PASADENA study of prasinezumab in pa...
Today Prothena Corporation ([[PRTA]] +28.7%) reached what could be its highest intraday gain in more than two years as Jefferies upgraded the stock to buy from neutral expecting a 100% upside to the stock.Citing the ‘positive momentum and pipeline execution’ and rising investor ...
Gainers: Artelo Biosciences (ARTL) +93%. ImmunoGen (IMGN) +29%. Prothena Corporation (PRTA) +26%. NantKwest (NK) +21%. Illumina (ILMN) +19%.Losers: Amicus Therapeutics (FOLD) -33%. CollPlant Biotechnologies (CLGN) -30%. Caladrius Biosciences (CLBS) -20%. Conformis (CFMS) -16%. SQZ Biotechnolo...
Prothena Corporation (PRTA) Q4 2020 Earnings Conference Call February 11, 2021 08:30 ET Company Participants Ellen Rose - Head of Communications Gene Kinney - President, Chief Executive Officer & Director Tran Nguyen - Chief Financial Officer & Chief Operating Officer Wagner Zago - Ch...
News, Short Squeeze, Breakout and More Instantly...
Prothena Corporation plc Company Name:
PRTA Stock Symbol:
NASDAQ Market:
Prothena Corporation plc Website:
2024-07-03 23:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-02 10:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Prothena to receive $80 million from Bristol Myers Squibb for exclusive global license to PRX019, a potential treatment of neurodegenerative diseases with an undisclosed target Prothena will initiate a Phase 1 clinical trial for PRX019 in 2024 Prothena Corporation plc (NASDAQ:PRTA),...